The cost-effectiveness of particle therapy in non-small cell lung cancer: Exploring decision uncertainty and areas for future research

Cancer Treatment Reviews

Volumn 36, Issue 6, 2010, Pages 468-476

  Grutters, Janneke P C ^a,b   Pijls Johannesma, Madelon ^a   Ruysscher, Dirk De ^a   Peeters, Andrea ^a   Reimoser, Stefan ^c   Severens, Johan L ^b,d   Lambin, Philippe ^a   Joore, Manuela A ^b,d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Turner and Townsend GmbH   (Germany)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carbon ions; Economic evaluation; Evidence synthesis; Lung cancer; Particle therapy; Protons

Indexed keywords

PROTON; CARBON; ION;

CANCER RADIOTHERAPY; CLINICAL RESEARCH; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DYSPNEA; ESOPHAGITIS; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PHOTON THERAPY; PROBABILITY; PROTON THERAPY; QUALITY ADJUSTED LIFE YEAR; RADIATION PNEUMONIA; REVIEW; STATISTICAL MODEL; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC TREATMENT; TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; ECONOMICS; LUNG NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC); RADIOSURGERY; RADIOTHERAPY;

CARBON; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; IONS; LUNG NEOPLASMS; MARKOV CHAINS; PROTONS; QUALITY-ADJUSTED LIFE YEARS; RADIOSURGERY; RADIOTHERAPY;

EID: 77956306556     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.02.018     Document Type: Review

References (48)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Youlden D.R., Cramb S.M., Baade P.D. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008, 3:819-831.
3. Meropol N.J., Schrag D., Smith T.J., et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009, 27:3868-3874.
4. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, Oxford. 3rd ed.
5. Grutters JPC, Kessels AGH, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for stage I to III non-small cell lung cancer: a meta-analysis. Radiother Oncol, in press. doi:10.1016/j.radonc.2009.08.003. doi:10.1016/j.radonc.2009.08.003.
6. Pijls-Johannesma M., Grutters J.P., Lambin P., Ruysscher D.D. Particle therapy in lung cancer: where do we stand?. Cancer Treat Rev 2008.
7. Weinstein M.C., O'Brien B., Hornberger J., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003, 6:9-17.
8. Briggs A., Sculpher M., Claxton K. Decision modelling for health economic evaluation 2006, Oxford University Press, Oxford.
9. Claxton K., Sculpher M., Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002, 360:711-715.
10. Glatstein E., Glick J., Kaiser L., Hahn S.M. Should randomized clinical trials be required for proton radiotherapy? An alternative view. J Clin Oncol 2008, 26:2438-2439.
11. Goitein M., Cox J.D. Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol 2008, 26:175-176.
12. Anonymous Introducing new treatments, technologies into the clinic. J Clin Oncol 2008, 26:2425.
13. Glimelius B., Montelius A. Proton beam therapy - do we need the randomised trials and can we do them?. Radiother Oncol 2007, 83:105-109.
14. Goitein M. Magical protons?. Int J Radiat Oncol Biol Phys 2008, 70:654-656.
15. Lewis B.E. On equipoise and emerging technologies. J Clin Oncol 2008, 26:2590.
16. Macbeth F.R., Williams M.V. Proton therapy should be tested in randomized trials. J Clin Oncol 2008, 26:2590-a-1.
17. Morgan J.P. A patient's perspective on randomized clinical trials for proton radiotherapy. J Clin Oncol 2008, 26:2592.
18. Suit H., Kooy H., Trofimov A., et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted?. No Radiother Oncol 2008, 86:148-153.
19. Tepper J.E. Protons and parachutes. J Clin Oncol 2008, 26:2436-2437.
20. Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE). ; 2006 [accessed 03.02.2010]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
21. Hall E.J. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006, 65:1-7.
22. Paganetti H. The impact of protons on the incidence of second malignancies in radiotherapy by Eric J. Hall (Supp.31-34; 2007). Technol Cancer Res Treat, 2007;6:661-662.
23. Paganetti H, Bortfeld T, Delaney TF. Neutron dose in proton radiation therapy: in regard to Eric J. Hall (Int J Radiat Oncol Biol Phys, 2006;65:1-7). Int J Radiat Oncol Biol Phys, 2006;66:1594-1595 [author reply 5].
24. Onishi H., Shirato H., Nagata Y., et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2:S94-S100.
25. Uematsu M., Shioda A., Suda A., et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001, 51:666-670.
26. Miyamoto T., Baba M., Sugane T., et al. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol 2007, 2:916-926.
27. Miyamoto T., Baba M., Yamamoto N., et al. Curative treatment of stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys 2007, 67:750-758.
28. The EuroQol Group EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208.
29. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108.
30. Health Care Insurance Board Guidelines for pharmaco-economic research (in Dutch) 2006, Health Care Insurance Board, Diemen.
31. Oostenbrink J.B., Koopmanschap M.A., Rutten F.F.H. Manual for costing research (in Dutch) 2004, College voor zorgverzekeringen, Amstelveen.
32. Peeters A, Grutters JPC, Pijls-Johannesma M, et al. How costly is radiotherapy with particles? Cost analysis of external beam radiotherapy with carbon ions, protons and photons. Radiother Oncol, in press. doi:10.1016/j.radonc.2009.12.002. doi:10.1016/j.radonc.2009.12.002.
33. Council for Public Health and Health Care Sensible and sustainable care (in Dutch) 2006, Council for Public Health and Health Care, Zoetermeer.
34. van Hout B.A., Al M.J., Gordon G.S., Rutten F.F. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994, 3:309-319.
35. Hoyer M. Improved accuracy and outcome in radiotherapy of lung cancer. Radiother Oncol 2008, 87:1-2.
36. Claxton K., Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996, 5:513-524.
37. Dutch Cancer Registry. ; 2010 [accessed 12.02.2010]. http://www.ikcnet.nl/index.php.
38. Welte R., Feenstra T., Jager H., Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004, 22:857-876.
39. Wild C., Langer T. Emerging health technologies: informing and supporting health policy early. Health Policy 2008, 87:160-171.
40. Willan A., Kowgier M. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. Clin Trials 2008, 5:289-300.
41. Cox J.D., Chang J., Liao Z., et al. Acute esophageal reactions from proton beam therapy, concurrent chemotherapy for non-small cell lung cancer (NSCLC): reduction in incidence, severity despite higher doses. J Thorac Oncol 2007, 2:S449.
42. Komaki R, Sejpal SV, Wei X, et al. Reduction of bone marrow suppression for patients with stage III NSCLC treated by proton and chemotherapy compared with IMRT and chemotherapy. In: Conference of the particle therapy co-operative group, vol. 47. Jacksonville, Florida; 2008. p. 14.
43. Sejpal SV, Komaki R, Wei X, et al. Does proton beam radiotherapy (PBT) reduce treatment related pneumonitis (TRP) compared to intensity modulated related radiation therapy (IMRT) in patients with locally advanced non-small cell lung cancer (NSCLC) treated with concurrent chemotherapy? In: Conference of the particle therapy co-operative group, vol. 47. Jacksonville, Florida; 2008. p. 22.
44. Collins R., Fenwick E., Trowman R., et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 2007, 11. p. iii-iv, xv-xviii, 1-179.
45. Garside R., Pitt M., Somerville M., Stein K., Price A., Gilbert N. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess 2006, 10. p. 1-142, iii-iv.
46. Hassan C., Pickhardt P.J., Di Giulio E., Hunink M.G., Zullo A., Nardelli B.B. Value-of-information analysis to guide future research in the management of the colorectal malignant polyp. Dis Colon Rectum 2010, 53:135-142.
47. Carlson J.J., Garrison L.P., Ramsey S.D., Veenstra D.L. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 2009, 12:20-27.
48. Eckermann S., Willan A.R. Expected value of information and decision making in HTA. Health Econ 2007, 16:195-209.